 | | Vol. 12.25 – 02 July, 2020 |
| |
|
|
| Using the sleeping beauty transposon system in Brca1-deficient mice, researchers identified 169 putative cancer drivers, among which Notch1 was a top candidate for accelerating TNBC by promoting the epithelial-mesenchymal transition and regulating the cell cycle.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that Gal-GalNAc levels increased as human breast cancer progressed, and that occurrence of F. nucleatum gDNA in breast cancer samples correlated with high Gal-GalNAc levels.
[Nature Communications] |
|
|
|
| The authors demonstrated that fibroblasts reduced lapatinib sensitivity in a subset of HER2+ breast cancer cells via paracrine signaling that could be reversed by targeting downstream survival programs such as MTOR and antiapoptotic proteins.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists report new non-canonical regulatory properties of ultra-selective histone deacetylase inhibitors over the expression and function of epithelial-mesenchymal transition pathways and the invasiveness potential of breast cancer.
[Cancer Research] |
|
|
|
| Investigators demonstrated that the histone binding function of Pygopus 2 was important for driving de-differentiation and malignancy of breast tumors, and loss of this binding activated various differentiation pathways which attenuated primary tumor growth and metastasis formation.
[Cancer Research] |
|
|
|
| Researchers designed a mitochondrial targeted drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers to simultaneously inhibit breast cancer progression and metastasis.
[Journal of Controlled Release] |
|
|
|
| The authors report for the first time that DHW-208 suppressed the growth of human breast cancer cells by inhibiting the PI3K/AKT/mTOR-signaling pathway both in vivo and in vitro.
[Cell Death & Disease] |
|
|
|
| Scientists showed that Protein kinase C theta regulated the sensitivity of TNBC cells to apoptosis triggered by standard-of-care chemotherapy by regulating levels of pro-apoptotic Bim.
[Breast Cancer Research] |
|
|
|
| The authors introduced a novel “all-in-one nanosoldier” made of colloidal hybrid nanostructures, which were designed for simultaneously targeting, imaging, and killing TNBC cells. The results demonstrated that this novel strategy was highly effective for targeting and killing TNBC cells in vitro, expressing high levels of folate membrane-receptors.
[Journal of Materials Chemistry B] |
|
|
|
| Researchers presented an alternate method to culture individually selected cells in relative isolation from the rest of the population under physiologically relevant matrix conditions. Using examples of breast and colorectal cancers, scientists showed that individual cells evolved into tumors or aspects of tumors displaying different characteristics of the initial cancer type and aggressiveness.
[Scientific Reports] |
|
|
|
|
| The authors review the latest literature describing the structure of the mammary gland and the breast cancer microenvironment (BCM) and summarize the influence of epithelial-mesenchymal transition and autophagy in breast cancer dissemination.
[Cancers] |
|
|
|
|
| Oncolytics Biotech® Inc announced a new investigator-sponsored triple-negative breast cancer study to be managed by Rutgers Cancer Institute of New Jersey. The phase II trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte’s anti-PD-1 checkpoint inhibitor retifanlimab in patients with unresectable locally advanced or metastatic TNBC.
[Oncolytics Biotech] |
|
|
|
| The UK government plans to set up an “office for talent” to oversee visas and make it easier to attract top scientists after Brexit, according to an R&D road map.
[ScienceInsider] |
|
|
|
| Academics in Hong Kong are facing new worries today after the mainland government abruptly imposed a controversial new security law that critics say could infringe on human rights and chill academic freedom.
[ScienceInsider] |
|
|
|
|
| October 9 – October 12
San Diego, California, United States |
|
|
|
|
|
| | University of Virginia – Charlottesville, Virginia, United States |
|
|
|
| | Mayo Clinic – Rochester, Minnesota, United States |
|
|
|
| | University of Oklahoma Health Science Center – Oklahoma City, Oklahoma, United States |
|
|
|
| | University of Vermont – Burlington, Vermont, United States |
|
|
|
| | Georgetown University Medical Center – Washington, District of Columbia, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
